Wall Street brokerages expect Silk Road Medical Inc (NASDAQ:SILK) to announce $17.90 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Silk Road Medical’s earnings, with estimates ranging from $17.80 million to $18.00 million. The company is expected to issue its next quarterly earnings report on Tuesday, February 4th.

According to Zacks, analysts expect that Silk Road Medical will report full-year sales of $62.61 million for the current financial year, with estimates ranging from $62.52 million to $62.70 million. For the next year, analysts expect that the company will report sales of $93.86 million, with estimates ranging from $93.71 million to $94.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Silk Road Medical.

Silk Road Medical (NASDAQ:SILK) last posted its earnings results on Tuesday, October 29th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The business had revenue of $17.00 million during the quarter, compared to analyst estimates of $15.93 million. Silk Road Medical’s revenue for the quarter was up 77.1% compared to the same quarter last year.

Several analysts have issued reports on SILK shares. Zacks Investment Research upgraded Silk Road Medical from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research note on Saturday, November 2nd. Argus started coverage on Silk Road Medical in a research note on Tuesday, August 20th. They issued a “buy” rating and a $52.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $43.50.

NASDAQ:SILK traded down $0.72 on Monday, reaching $34.88. The company’s stock had a trading volume of 282,400 shares, compared to its average volume of 277,238. The company has a quick ratio of 13.38, a current ratio of 14.32 and a debt-to-equity ratio of 0.53. The business’s 50-day moving average price is $33.11 and its two-hundred day moving average price is $40.02. Silk Road Medical has a 1-year low of $27.83 and a 1-year high of $51.50.

In other Silk Road Medical news, major shareholder Pincus & Co. Warburg sold 630,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $39.50, for a total value of $24,885,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

A number of large investors have recently added to or reduced their stakes in the business. TimesSquare Capital Management LLC raised its stake in Silk Road Medical by 55.1% in the third quarter. TimesSquare Capital Management LLC now owns 600,952 shares of the company’s stock valued at $19,549,000 after buying an additional 213,402 shares during the period. SG Americas Securities LLC bought a new stake in Silk Road Medical in the third quarter valued at approximately $834,000. California Public Employees Retirement System increased its stake in shares of Silk Road Medical by 60.7% during the third quarter. California Public Employees Retirement System now owns 7,608 shares of the company’s stock worth $247,000 after purchasing an additional 2,874 shares during the period. Steward Partners Investment Advisory LLC increased its stake in shares of Silk Road Medical by 50.6% during the third quarter. Steward Partners Investment Advisory LLC now owns 2,620 shares of the company’s stock worth $85,000 after purchasing an additional 880 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Silk Road Medical by 72.1% during the third quarter. Rhumbline Advisers now owns 11,560 shares of the company’s stock worth $376,000 after purchasing an additional 4,843 shares during the period. Hedge funds and other institutional investors own 70.53% of the company’s stock.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Featured Story: What is Green Investing?

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.